Cargando…
Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
BACKGROUND: Patient preferences are key parameters to evaluate benefit-harm balance of statins for primary prevention but they are not readily available to guideline developers and decision makers. Our study aimed to elicit patient preferences for benefit and harm outcomes related to use of statins...
Autores principales: | Yebyo, Henock G., Aschmann, Hélène E., Yu, Tsung, Puhan, Milo A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960214/ https://www.ncbi.nlm.nih.gov/pubmed/29776337 http://dx.doi.org/10.1186/s12872-018-0838-9 |
Ejemplares similares
-
Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
por: Yebyo, Henock G., et al.
Publicado: (2020) -
Net benefit of statins for primary prevention of cardiovascular
disease in people 75 years or older: a benefit–harm balance modeling
study
por: Yebyo, Henock G., et al.
Publicado: (2019) -
Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023) -
Should statins be considered for the management of mucormycosis in COVID-19?
por: Chatterjee, Subhankar, et al.
Publicado: (2021) -
Outcome preferences of older people with multiple chronic conditions and hypertension: a cross-sectional survey using best-worst scaling
por: Aschmann, Hélène E., et al.
Publicado: (2019)